Patent US4465660A successfully refreshed from Google Patents.
US4465660A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release tablet containing at least 95 percent theophylline
Assignee: Mead Johnson and Co LLC
•
Filing: 1982-12-21
•
Granted: 1984-08-14
•
Expires: 2002-12-21
Abstract
Abstract Non-disintegrating theophylline tablets having a pair of opposing substantially planar surfaces and a very thin cross-section have a high bioavailability on ingestion and a relatively steady release rate permitting a 12 hr. dosing interval for maintenance of non-toxic therapeutic blood theophylline concentrations. Excipients or tableting aids are not required, but trace amounts of a tableting lubricant are preferably included to facilitate continuous large scale production.
Inventors
- 👤 Stephen T. David
- 👤 Dana Brooke
- 👤 Claude E. Gallian
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 21:34
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K9/00; A61K9/20; A61K9/2072
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
112 words
A sustained release pharmaceutical tablet comprising 95% to 99.8% by weight of theophylline, and the remainder conventional pharmaceutical tablet ingredients selected to provide a tablet that remains intact during dissolution, said tablet having a pair of substantially planar opposing faces joined by edge walls and a thickness of from 0.08 to 0.12 inches which when administered to a human in a therapeutically effective amount at consecutive 12 hour intervals affords a continuous blood serum concentration of from 10 mcg/ml to 20 mcg/ml of theophylline during said intervals and wherein said tablet has a bisect score on one of said planar faces and a pair of trisect scores on the opposing planar face.
Claim 2
Dependent Claim
112 words
A sustained release pharmaceutical tablet comprising 95% to 99.8% by weight of theophylline, and the remainder conventional pharmaceutical tablet ingredients selected to provide a tablet that remains intact during dissolution, said tablet having a pair of substantially planar opposing faces joined by edge walls and a thickness of from 0.08 to 0.12 inches which when administered to a human in a therapeutically effective amount at consecutive 12 hour intervals affords a continuous blood serum concentration of from 10 mcg/ml to 20 mcg/ml of theophylline during said intervals and wherein said tablet has a bisect score on one of said planar faces and a pair of trisect scores on the opposing planar face.
Claim 3
Dependent Claim
14 words
The pharmaceutical tablet of claim 1 containing 100 mg to 500 mg of theophylline.
Claim 4
Dependent Claim
14 words
The pharmaceutical tablet of claim 1 having a thickness of 0.09 to 0.11 inches.
Claim 5
Dependent Claim
19 words
The pharmaceutical tablet of claim 1 containing from 0.2% to 0.6% by weight of magnesium stearate as tableting lubricant.
Claim 6
Dependent Claim
18 words
The pharmaceutical tablet of claim 1 containing 0.3% to 0.5% by weight of magnesium stearate as tableting lubricant.
Claim 7
Dependent Claim
21 words
The pharmaceutical tablet of claim 1 consisting essentially of 99.6% by weight of theophylline and 0.4% by weight of magnesium stearate.
Claim 8
Dependent Claim
11 words
The pharmaceutical tablet of claim 6 containing 300 mg of theophylline.
Claim 9
Dependent Claim
13 words
The pharmaceutical tablet of claim 7 wherein said edge walls define a rectangle.
Claim 10
Dependent Claim
118 words
A sustained release pharmaceutical tablet consisting essentially of 99.4% to 99.8% by weight of theophylline and 0.1% to 0.6% by weight of a tableting lubricant selected to provide a tablet that remains intact during dissolution, said tablet having a pair of substantially planar opposing faces joined by edge walls and a thickness of from 0.08 to 0.12 inches which when administered to a human in a therapeutically effective amount at consecutive 12 hour intervals affords a continuous blood serum concentration of from 10 mcg/ml to 20 mcg/ml of theophylline during said intervals and wherein said tablet has a bisect score on one side of said planar faces and a pair of trisect scores on the opposing planar face.
Claim 11
Dependent Claim
118 words
A sustained release pharmaceutical tablet consisting essentially of 99.4% to 99.8% by weight of theophylline and 0.1% to 0.6% by weight of a tableting lubricant selected to provide a tablet that remains intact during dissolution, said tablet having a pair of substantially planar opposing faces joined by edge walls and a thickness of from 0.08 to 0.12 inches which when administered to a human in a therapeutically effective amount at consecutive 12 hour intervals affords a continuous blood serum concentration of from 10 mcg/ml to 20 mcg/ml of theophylline during said intervals and wherein said tablet has a bisect score on one side of said planar faces and a pair of trisect scores on the opposing planar face.
Claim 12
Dependent Claim
12 words
The tablet of claim 9 where the tableting lubricant is magnesium stearate.
Claim 13
Dependent Claim
141 words
A pharmaceutical tablet for the maintenance of a therapeutically effective blood concentration of theophylline during a dosage interval of up to 12 hours following ingestion thereof in therapeutically effective amount comprised of at least 95% by weight of theophylline and the remainder conventional pharmaceutical tablet ingredients selected to provide a tablet which dissolves without first disintegrating when contacted with water during a period of about 4 hours to the extent of from 83% to 100% by weight, wherein said tablet has a pair of substantially planar opposing faces joined by edge walls and a thickness of from 0.08 to 0.12 inches and the therapeutically effective theophylline blood serum concentration maintained by said tablet is substantially within the range of from about 10 mcg/ml to 20 mcg/ml and wherein said tablet has score lines arranged for both bisecting and trisecting the tablet.
Claim 14
Dependent Claim
141 words
A pharmaceutical tablet for the maintenance of a therapeutically effective blood concentration of theophylline during a dosage interval of up to 12 hours following ingestion thereof in therapeutically effective amount comprised of at least 95% by weight of theophylline and the remainder conventional pharmaceutical tablet ingredients selected to provide a tablet which dissolves without first disintegrating when contacted with water during a period of about 4 hours to the extent of from 83% to 100% by weight, wherein said tablet has a pair of substantially planar opposing faces joined by edge walls and a thickness of from 0.08 to 0.12 inches and the therapeutically effective theophylline blood serum concentration maintained by said tablet is substantially within the range of from about 10 mcg/ml to 20 mcg/ml and wherein said tablet has score lines arranged for both bisecting and trisecting the tablet.
Claim 15
Dependent Claim
16 words
The pharmaceutical tablet of claim 11 containing from about 100 mg to 500 mg of theophylline.
Claim 16
Dependent Claim
38 words
The pharmaceutical tablet of claim 11 which when administered to a human in bronchodilative effective amount at consecutive intervals of from about 8 to 12 hours maintains a bronchodilative effective blood serum concentration of theophylline during said interval.
Claim 17
Dependent Claim
14 words
The pharmaceutical tablet of claim 11 having a thickness of 0.09 to 0.11 inches.
Claim 18
Dependent Claim
18 words
The pharmaceutical tablet of claim 11 containing at least 99% by weight of theophylline and a tableting lubricant.
Claim 19
Dependent Claim
19 words
The pharmaceutical tablet of claim 15 containing from 0.1% to 0.6% by weight of magnesium stearate as tableting lubricant.
Claim 20
Dependent Claim
19 words
The pharmaceutical tablet of claim 15 containing from 0.3% to 0.5% by weight of magnesium stearate as tableting lubricant.
Claim 21
Dependent Claim
21 words
The pharmaceutical tablet of claim 11 consisting essentially of 99.6% by weight of theophylline and 0.4% by weight of magnesium stearate.
Claim 22
Dependent Claim
11 words
The pharmaceutical tablet of claim 11 containing 300 mg of theophylline.
Claim 23
Dependent Claim
29 words
The pharmaceutical tablet of claim 11 having a bisect score line on one of said planar faces and a pair of trisect score lines on the opposing planar face.
Claim 24
Dependent Claim
13 words
The pharmaceutical tablet of claim 11 wherein said edge walls define a rectangle.
Claim 25
Dependent Claim
28 words
The pharmaceutical tablet of claim 11 wherein said tablet consists essentially of 99.4% to 99.8% by weight of theophylline and 0.1% to 0.6% by weight of magnesium stearate.
Claim 26
Dependent Claim
12 words
The pharmaceutical tablet of claim 21 having a thickness of 0.1 inches.
References Cited (Backward Citations)
US3402240A
Cited
US2980589A
Cited
US3079303A
Cited
US3062720A
Cited
US3065143A
Cited
US3080294A
Cited
US3108046A
Cited
US3133863A
Cited
US3148124A
Cited
US3279998A
Cited
US3147187A
Cited
US3279995A
Cited
US3344029A
Cited
US3424842A
Cited
US3456049A
Cited
US3641236A
Cited
US3507952A
Cited
US3639169A
Cited
US3622677A
Cited
US3870790A
Cited
US3852421A
Cited
US3632778A
Cited
US3782993A
Cited
US3908003A
Cited
US3773920A
Cited
US3950508A
Cited
US4209513A
Cited
US4017598A
Cited
US4167558A
Cited
EP0010876A1
Cited
US4215104A
Cited
US4258027A
Cited
JPS55153715A
Cited
US4264573A
Cited
US4361545A
Cited
US4226849A
Cited
US4259314A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-08-14 | 1988-02-13 | 1988-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-08-14 | 1992-02-13 | 1992-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-08-14 | 1996-02-13 | 1996-08-14 | $7700.00 | Window Closed / Lapsed |